Cancer diagnosis and treatment represents a significant expenditure in developed healthcare systems. Cancer screening is performed through routine tests such as complete blood counts (CBCs), differentials, and protein markers. However, the global oncology diagnostics market is quickly evolving past established markers and companion diagnostics in the United States, Europe and Japan. Targeted cancer therapies are finding significant demand in emerging middle-income countries such as China and new technologies such as liquid biopsies, next-generation sequencing (NGS) and novel hybridization assays are being developed for cancer detection and diagnosis. Kalorama Information market research covers cancer diagnostics from multiple angles of diagnostic technology and regional demand.